Scarica l'app Stockscreener
1.77
2.21%
-0.04
Dopo l'orario di chiusura:
1.77
Panoramica
Notizia
Cronologia dei prezzi
Perché EVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1.81
Aprire:
$1.77
Volume 24 ore:
23,949
Relative Volume:
0.43
Capitalizzazione di mercato:
$629.04M
Reddito:
$863.66M
Utile/perdita netta:
$-225.27M
Rapporto P/E:
-2.7909
EPS:
-0.6342
Flusso di cassa netto:
$-63.28M
1 W Prestazione:
-6.84%
1M Prestazione:
-14.90%
6M Prestazione:
-33.71%
1 anno Prestazione:
-48.09%
Intervallo 1D:
$1.7383
$1.77
Intervallo di 1 settimana:
$1.7383
$1.86
Portata 52W:
$1.7383
$4.27
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
1.77 | 643.25M | 863.66M | -225.27M | -63.28M | -0.6342 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Ripresa | H.C. Wainwright | Buy |
| 2026-02-03 | Iniziato | Berenberg | Buy |
| 2025-04-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2024-08-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-04-04 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-16 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-01-07 | Ripresa | Citigroup | Neutral |
Mostra tutto
Evotec Se Adr Borsa (EVO) Ultime notizie
Evotec SE (NASDAQ: EVO) Initiates First Human Trial for JST-018 Under 2023 Accelerated Antibodies Contract - Kalkine Media
Evotec starts Phase 1 trial for JST-018 antibody therapy - grafa.com
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Evotec stock struggles after profit warning as Q2 2026 figures and guidance cuts weigh on sentiment - ad-hoc-news.de
Evotec stock trades close to 52-week low as Q2 revenue declines - ad-hoc-news.de
Evotec stock trades at a discount to recent analyst targets as Xetra shares retreat - ad-hoc-news.de
Evotec stock trades well below analyst targets as selling pressure intensifies - Ad-hoc-news.de
Evotec stock faces earnings estimate cut as ADR trades below $2 - ad-hoc-news.de
Evotec AG Earnings Call: Weak 2026, Pipeline Hopes - The Globe and Mail
Evotec signs AI drug discovery partnership with Odyssey - grafa.com
Evotec SE (EVO) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesPost-Earnings Reaction - vinanet.vn
Berenberg cuts Evotec on delayed pharma deals clouding revenue outlook - Investing.com
Berenberg cuts Evotec stock rating on guidance downgrade By Investing.com - Investing.com Nigeria
Berenberg cuts Evotec stock rating on guidance downgrade - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
TD Cowen cuts Evotec on customer delays clouding growth outlook By Investing.com - Investing.com Nigeria
TD Cowen cuts Evotec on customer delays clouding growth outlook - Investing.com
H.C. Wainwright cuts Evotec stock price target on revenue guidance reduction - Investing.com
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com Nigeria
Earnings call transcript: Evotec cuts 2026 outlook as Q2 revenue falls - Investing.com Nigeria
Evotec slumps 32% after H1 loss widens, annual outlook slashed - Investing.com
Evotec stock. Thin source set keeps the focus on business context. - Ad Hoc News
EVTA Forecast — Price Target — Prediction for 2027 - TradingView
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec - news.financial
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec - news.financial
Evotec consensus picture on Wall Street, shares trade as ADR on NASDAQ - Ad-hoc-news.de
Evotec launches J.TRAIN for biologics manufacturing - grafa.com
Evotec consensus picture on Nasdaq EVO, shares hover around 2.74 dollars - ad-hoc-news.de
A0QZ3J Forecast — Price Target — Prediction for 2027 - TradingView
Evotec SE Sponsored ADR Actuals & Estimates (NASDAQ:EVO) - TradingView
Evotec refines analyst expectations, shares trade under 5 euros on Xetra - AD HOC NEWS
Evotec shows weak June performance, analyst consensus points above current shares - AD HOC NEWS
Evotec Stockweekly review and sector comparison - Ad-hoc-news.de
Which stock to buy now? Evotec, Nel, and Lahontan Gold in focus - news.financial
Evotec (EVO) Stock Price, News & Analysis $EVO - MarketBeat
Evotec SE Stock (DE0005664809): Short Interest Eases While Shares Trade Near Lows - AD HOC NEWS
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Nigeria
Evotec SE stock (DE0005664809): After CEO exit and audit delay, investors watch turnaround plans - AD HOC NEWS
EVO - Finviz
Evotec ADR Slides 4.3% as Selling Pressure Tests Key Support LevelsQuality Factor - The Legal Advocate
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus! - news.financial
BUY RECOMMENDATIONS for RENK and Desert Gold! SHOCK for Evotec! - news.financial
Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion - AD HOC NEWS
Evotec AG Earnings Call Balances Pain With Promise - The Globe and Mail
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth - AD HOC NEWS
Evotec places €116.1 million convertible bonds due 2033 - Investing.com UK
Evotec places €116.1 million convertible bonds due 2033 By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum - AD HOC NEWS
Evotec Se Adr Azioni (EVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.56%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):